Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

SFAS No. 123R. Amicus believes that excluding the

impact of expensing stock options better reflects the recurring

economic characteristics of its business.

(2) Other items -- Non-GAAP net loss and diluted net loss per common share

exclude other unusual or non-recurring items that are evaluated on an

individual basis. Amicus' evaluation of whether to exclude an item for

purposes of determining its non-GAAP financial measures considers both

the quantitative and qualitative aspects of the item, including, among

other things (i) its size and nature, (ii) whether or not it relates

to its ongoing business operations, and (iii) whether or not Amicus

expects it to occur as part of its normal business on a regular basis.

Items excluded for purposes of determining non-GAAP net loss and

diluted net loss per common share include deemed dividends, preferred

stock accretion, and changes in the fair value of warrant liability.

Conference Call and Webcast: First Quarter Financial Results

Amicus Therapeutics will host a conference call and webcast today, Tuesday, May 13, 2008, at 5:00 P.M. EDT to review financial results and recent developments. Interested participants and investors may access the teleconference call by dialing 877-397-0284 (U.S./Canada) or 719-325-4871 (international).

The webcast of the call can be accessed on the Investor section of Amicus' Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a replay will remain available in the Investors section of Amicus' Web site for 90 days.

A telephonic replay will also be available for seven days be
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014  InterMune, Inc. (NASDAQ: ITMN ... quarter 2014 financial results at the close of the ... call and webcast will be hosted by InterMune at ... Interested investors and others may participate in the conference ... conference ID#21728775. A replay of the webcast and teleconference will ...
(Date:7/25/2014)... Albany, NY (PRWEB) July 26, 2014 ... Trials Review, H2, 2014" provides data on the ... This report provides elemental information and data relating ... Cerebral Stroke. , View full global Ischemic Stroke ... It includes an overview of the trial numbers ...
(Date:7/25/2014)... July 25, 2014 According to a ... Drugs Market - Global Industry Analysis, Size, Share, Growth, ... drugs market is estimated at USD 161,056.5 million in ... of 10.1% from 2014 to 2020, to reach an ... The biological drugs market is witnessing a significant growth ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- Xybion Corporation, the leading provider of ... in highly regulated industries, announced today that the ... Group Conference, Xybion International Exchange, on October 21-23, ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance Fusion.  ...
Breaking Biology Technology:InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... leaders, experts and foreign ministry delegations set to be involved in ... ... Singapore (PRWEB) March 2, 2009 -- Asia-Pacific,s largest and most ... Asia 2009 (GSA 2009), will be held in Singapore from 17th ...
... LOUIS, Feb. 27 A copy of the Company,s December ... Exchange Commission, may be obtained without charge at our website ... Sigma-Aldrich Corporation, P. O. Box 14508, St. Louis, Missouri 63178. ... Life Science and High Technology ...
... CV Therapeutics, Inc. (Nasdaq: CVTX ) today ... time in response to Astellas Pharma Inc.,s announcement that ... unsolicited tender offer for all outstanding common shares of ... in cash. CV Therapeutics, board of directors, in ...
Cached Biology Technology:News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 2News Release: Homeland Security to Take Centre Stage with Global Security Asia 2009 3CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 2CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer 3
(Date:7/28/2014)... DUBLIN , July 28, 2014 ... the "Biometrics Market in Latin America 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 Biometrics measure and analyze biological ... facial patterns, irises, eye retinas, voice patterns, and hand ... one or more stored templates. The main purpose of ...
(Date:7/28/2014)... became the first man to reach the South Pole ... an international team of scientists led by Joe McConnell ... air pollution from industrial activities arrived long before. , ... spaced locations around the Antarctic continent, including the South ... reconstruction to date of lead pollution over the Earth,s ...
(Date:7/27/2014)... DURHAM, N.C. -- Microorganisms like bacteria and fungi can ... by antibiotics or antifungal drugs. These permanent mutations were ... strains to evolve. Now a new study has shown ... targets -- known as epimutations -- to gain the ... the new mechanism was discovered in a fungus called ...
Breaking Biology News(10 mins):Biometrics Market in Latin America 2014-2018 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Scientists discover new, noncommittal mechanism of drug resistance 2Scientists discover new, noncommittal mechanism of drug resistance 3
... of evolution is periodically marked by explosions in biodiversity, ... of shapes and sizes. With a new analysis of ... have discovered that these diversifications proceeded head-first. By ... around the time of two separate extinction events, scientists ...
... are fascinating plant organs they not only anchor the ... Roots live in darkness and direct the activities of the ... Charles Darwin posited in The Power of Movement of Plants ... Due to the difficulty of accessing root tissue in ...
... Mediterranean diet with large amounts of vegetables and fish gives ... studies to be published by the Sahlgrenska Academy at the ... shown that a Mediterranean diet, based on a high consumption ... products such as meat and milk, leads to better health., ...
Cached Biology News:'Head-first' diversity shown to drive vertebrate evolution 2'Head-first' diversity shown to drive vertebrate evolution 3New tool offers unprecedented access for root studies 2
... HRP Conjugation Kits are based on ... that are consistent and reproducible. This ... conjugate your protein or antibody, including ... buffer. Activated HRP is supplied ...
... Acridinium NHS ester can be ... nucleic acids. The covalently bound ... chemiluminescence in the presence of ... proteins can be used as ...
... designed to hold up to 6 strain chambers ... easy to use design ensures that cells grow ... stretching or compression. This unit allows you to ... to produce 64 unique strain settings. The instrument ...
... a novel procedure for the uniform amplification ... genome DNA from small samples. This method ... and highly reproducible amplification and labeling procedure ... REPLI-g Mini Kit module (QIAGEN) and a ...
Biology Products: